Stacey L. Berg

Baylor College of Medicine — United States

Medicine · Health Sciences

47h-index7.4kcitations220works3.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroblastoma Research and Treatments(46), Glioma Diagnosis and Treatment(41), Cancer therapeutics and mechanisms(41), Childhood Cancer Survivors' Quality of Life(30), Brain Metastases and Treatment(21)

Publications219 total

Supplementary Data from A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412
2025Open Access
Supplementary fig 1 from A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412
2025Open Access
364TiP Early detection of symptoms during chemo(immune)therapy treatment of metastatic breast cancer using ePRO and Fitbits: The SYMPHA trial
ESMO Real World Data and Digital Oncology·2025Open Access
Germline Cancer Predisposition Results From the National Cancer Institute—Children's Oncology Group Pediatric MATCH Trial
JCO Precision Oncology·2025Open Access
Psychosocial distress and quality of life in families with a germline CDKN2A pathogenic variant
Pancreatology·2024
Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D
JCO Precision Oncology·2024· 4 citedOpen Access
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I)
JCO Precision Oncology·2024· 7 citedOpen Access
Phase 1 study of NEDD8 activating enzyme inhibitor pevonedistat in combination with chemotherapy in pediatric patients with recurrent or refractory solid tumors (ADVL1615)
European Journal of Cancer·2024· 8 citedOpen Access
Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G
The Oncologist·2024· 6 citedOpen Access
Vincristine (VCR) pharmacokinetics (PK) in infants dosed using a body surface area (BSA) banded dosing table and in older children dosed based on BSA: A pediatric early phase clinical trial network study (PEPN22P1).
Journal of Clinical Oncology·2024
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
JCO Precision Oncology·2024· 9 citedOpen Access
Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial
The Oncologist·2024· 6 citedOpen Access
A phase 1 trial utilizing a pharmacokinetic endpoint to determine the optimal dose of ramucirumab in children and adolescents with relapsed or refractory solid tumors, including central nervous system tumors
Pediatric Blood & Cancer·2024Open Access
EPINEPHRINE ADMINISTERED VIA SUBLINGUAL FILM, MANUAL INJECTION, OR AUTO-INJECTORS IN HEALTHY ADULTS: PHARMACODYNAMIC Results
Annals of Allergy Asthma & Immunology·2023
Palbociclib in solid tumor patients with genomic alterations in the cyclin D-CDK4/6-INK4a-Rb pathway: Results from NCI-COG pediatric MATCH trial Arm I (APEC1621I).
Journal of Clinical Oncology·2023· 4 cited
Erdafitinb in patients with FGFR-altered tumors: Results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B).
Journal of Clinical Oncology·2023· 17 cited
Update for NCI-COG Pediatric MATCH: Active trial cohorts for children, adolescents and young adults with refractory cancers.
Journal of Clinical Oncology·2023· 3 cited
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C
JNCI Journal of the National Cancer Institute·2023· 79 citedOpen Access
Abstract CT090: PEPN2011: a phase 1/2 study of tegavivint in children, adolescents, and young adults with recurrent or refractory solid tumors, including lymphomas and desmoid tumors: a report from the pediatric early phase clinical trials network
Cancer Research·2023· 3 cited
Data from A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412
2023Open Access
page 1 of 11Next →

Frequent Co-authors

Susan M. Blaney(22), Frank M. Balis(16), Peter C. Adamson(11), Elizabeth Fox(10), Joel M. Reid(8), Stephan D. Voss(7), Brenda J. Weigel(7), David G. Poplack(7), Mark Krailo(6), Charles G. Minard(6), Gregory H. Reaman(5), D. Williams Parsons(4), Nancy L. Pedersen(4), Gerald E. McClearn(4), Lisa Bomgaars(4), J. Russell Geyer(4), Roger J. Packer(4), Andrea Denicoff(4), Sharon E. Plon(3), Margaret Gatz(3)